Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 17Terminated 4Active not recruiting 3Unknown 2Recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 64Gastrointestinal 46Genitourinary 23Breast 18Head & Neck 12Gynecologic 12Dermatologic 6Sarcoma 5Tumor-Agnostic 3Other solid neoplasm 3CNS 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Melanoma 1Locally Advanced or Metastatic Solid Tumours 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumours 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 27Nivolumab 11Pemetrexed 10Cyclophosphamide 10Carboplatin 10atezolizumab 9Specimen Handling 8Cisplatin 8Ipilimumab 6Biopsy 6Injections 5tislelizumab 4spartalizumab 4fludarabine 4Vincristine 4Radiotherapy 4Proton Therapy 4Platinum 4Paclitaxel 4Drug Therapy 4Docetaxel 4Bevacizumab 41,2-diaminocyclohexaneplatinum II citrate 4durvalumab 3Trastuzumab 3Etoposide 3Cetuximab 3zimberelimab 2trametinib 2tocilizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × durvalumab × Other solid neoplasm × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
14 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡